Opinion

Video

Prostate Cancer Treatment: Visibility Considerations With Radiation

Author(s):

Brian Mazzarella, MD,Jeffrey T. Schiff, MD, MPH

The expert panel outlines visibility considerations with the 3 rectal spacer options when treating patients with prostate cancer with radiation therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Rana McKay, MD, on the role of radium-223 in the modern era
      Rana McKay, MD, on the role of radium-223 in the modern era
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses PSA kinetics in mHSPC
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      The importance of PSADT in high-risk, biochemically recurrent prostate cancer
      Related Content
      Urologists perform first remote robot-assisted HIFU for prostate cancer
      April 17th 2025

      Urologists perform first remote robot-assisted HIFU for prostate cancer

      Hannah Clarke
      “We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Study underway to assess 3-fraction SBRT regimen in prostate cancer
      April 14th 2025

      Study underway to assess 3-fraction SBRT regimen in prostate cancer

      Hannah Clarke
      "The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Genetic test can predict risk of toxicity following radiation for prostate cancer
      April 7th 2025

      Genetic test can predict risk of toxicity following radiation for prostate cancer

      Hannah Clarke
      "This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
      What urologists can expect in Q2 of 2025
      April 7th 2025

      What urologists can expect in Q2 of 2025

      Hannah Clarke Benjamin P. Saylor
      A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
      © 2025 MJH Life Sciences

      All rights reserved.